3.2 Association between use of individual SSRIs and risk of
UGIB
Nearly half (48.3%) of the patients in the case group were fluoxetine
users, and the second most prescribed SSRIs was sertraline (39.1%)
(Table 2). After adjusting for potential confounders, fluoxetine users,
compared with non-users of fluoxetine (i.e., users of other classes of
SSRIs), were at increased risk of UGIB (adjusted OR: 1.25, 95% CI:
1.03–1.50). However, compared with other classes of SSRIs, paroxetine
use was associated with a reduction in the risk of UGIB (adjusted OR:
0.71, 95% CI: 0.56–0.91). We did not observe significant associations
between use of citalopram, sertraline, fluvoxamine, and escitalopram and
risk of UGIB.